case_images: PMC11217479_01
case_images: The patient's CT scans at baseline, at best response, and at the last evaluation. (A-C) Evolution of a left supraventricular node. (D-F) Retroperitoneal node. The images in (A) and (D) were taken before starting immunotherapy treatment, while the images in (B) and (E) are those at the best response (this patient experienced a partial response with a -76% reduction in the target lesions). The images in (C) and (F) are the last scans of the patient in January 2024, when the decision to stop the treatment was made after 34 months. The red lines denote measurable disease.
case_images: fonc-14-1396869-g001.jpg
case_images: PMC11217479_01_fonc-14-1396869-g001.jpg
case_images: f1
case_images: Based on the MSI-H result, the patient was enrolled in a basket clinical trial, in which he underwent treatment for 34 months with second-line atezolizumab with partial response (-76%) and complete metabolic response with excellent treatment tolerance ( Figure 1 ).
case_images: Timeline of the clinical case presentation. PD, progressive disease.
case_images: fonc-14-1396869-g002.jpg
case_images: PMC11217479_01_fonc-14-1396869-g002.jpg
case_images: f2
case_images: The diagnosis and the treatment process of the patient are displayed in  Figure 2 .